Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9291877 | 0.95 | ESR2 (0.58) | ESR2TP53TSHRHDAC8HDAC6 | |
| SCHEMBL13163346 | 0.89 | ESR2 (0.50) | ESR2TP53TSHRHDAC8HDAC6 | |
| SCHEMBL3703059 | 0.89 | ESR2 (0.50) | ESR2TP53TSHRHDAC8HDAC6 | |
| SCHEMBL3694633 | 0.89 | ESR2 (0.50) | ESR2TP53TSHRHDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL3708308 | 0.87 | ESR2 (0.49) | ESR2TP53TSHRHDAC8HDAC6 | |
| SCHEMBL901209 | 0.86 | TSHR (0.57) | ESR2TP53TSHRHDAC8HDAC6 | |
| SCHEMBL901207 | 0.86 | TSHR (0.57) | ESR2TP53TSHRHDAC8HDAC6 | |
| SCHEMBL2321634 | 0.86 | TSHR (0.57) | ESR2TP53TSHRHDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL4290507 | 0.84 | TSHR (0.55) | ESR2TP53TSHRHDAC8HDAC6 | |
| SCHEMBL14403055 | 0.83 | ESR2 (0.78) | ESR2HDAC8HDAC6HDAC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-109952300-B | 5-or 8-substituted imidazo [1,5-a ] pyridines | 百济神州有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| CN-109952300-A | As indoleamine 2, imidazo [1,5-a] pyridine of the novel 5 or 8- substitution of 3- dioxygenase enzyme and/or tryptophan 2,3- dioxygenase enzyme selectivity inhibitor | 百济神州有限公司 | 2019-06-28 | — | — | CN | disclosed |
| WO-2018054365-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2018-03-29 | — | — | WO | disclosed |
| EP-2391611-B1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| EP-2391611-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
| EP-1341753-B1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-09-26 | — | — | EP | disclosed |
| CN-1678591-A | Novel carboxamide compounds having MCH-antagonistic action, pharmaceutical preparations comprising said compounds and process for their preparation | BOEHRINGER INGELHEIM INT (DE) | 2005-10-05 | — | — | CN | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1341753-A1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002044139-A1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | IDO1, TPH1, IDO2 | ESR2 4151/4885TP53 2731/4885TSHR 1187/4885 |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | ESR2 796/4885TP53 4875/4885TSHR 85/4885 |
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | ESR2 473/4885TP53 76/4885TSHR 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.